PMID- 28867364
OWN - NLM
STAT- MEDLINE
DCOM- 20181108
LR  - 20220129
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Print)
IS  - 0028-3908 (Linking)
VI  - 134
IP  - Pt B
DP  - 2018 May 15
TI  - Cell-based and pharmacological neurorestorative therapies for ischemic stroke.
PG  - 310-322
LID - S0028-3908(17)30399-4 [pii]
LID - 10.1016/j.neuropharm.2017.08.036 [doi]
AB  - Ischemic stroke remains one of most common causes of death and disability 
      worldwide. Stroke triggers a cascade of events leading to rapid neuronal damage 
      and death. Neuroprotective agents that showed promise in preclinical experiments 
      have failed to translate to the clinic. Even after decades of research, tPA 
      remains the only FDA approved drug for stroke treatment. However, tPA is 
      effective when administered 3-4.5 h after stroke onset and the vast majority of 
      stroke patients do not receive tPA therapy. Therefore, there is a pressing need 
      for novel therapies for ischemic stroke. Since stroke induces rapid cell damage 
      and death, neuroprotective strategies that aim to salvage or replace injured 
      brain tissue are challenged by treatment time frames. To overcome the barriers of 
      neuroprotective therapies, there is an increasing focus on neurorestorative 
      therapies for stroke. In this review article, we provide an update on 
      neurorestorative treatments for stroke using cell therapy such as bone marrow 
      derived mesenchymal stromal cells (BMSCs), human umbilical cord blood cells 
      (HUCBCs) and select pharmacological approaches including Minocycline and 
      Candesartan that have been employed in clinical trials. This review article 
      discusses the present understanding of mechanisms of neurorestorative therapies 
      and summarizes ongoing clinical trials. This article is part of the Special Issue 
      entitled 'Cerebral Ischemia'.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Venkat, Poornima
AU  - Venkat P
AD  - Department of Neurology, Henry Ford Hospital, Detroit, MI, 48202, USA.
FAU - Shen, Yi
AU  - Shen Y
AD  - Department of Neurology, Henry Ford Hospital, Detroit, MI, 48202, USA; 
      Gerontology Institute, Department of Neurology, Tianjin Medical University 
      General Hospital, Tianjin Neurological Institute, Key Laboratory of 
      Post-Neurotrauma Neurorepair and Regeneration in Central Nervous System, Ministry 
      of Education and Tianjin City, Tianjin, 300052, China.
FAU - Chopp, Michael
AU  - Chopp M
AD  - Department of Neurology, Henry Ford Hospital, Detroit, MI, 48202, USA; Department 
      of Physics, Oakland University, Rochester, MI, 48309, USA.
FAU - Chen, Jieli
AU  - Chen J
AD  - Department of Neurology, Henry Ford Hospital, Detroit, MI, 48202, USA; 
      Gerontology Institute, Department of Neurology, Tianjin Medical University 
      General Hospital, Tianjin Neurological Institute, Key Laboratory of 
      Post-Neurotrauma Neurorepair and Regeneration in Central Nervous System, Ministry 
      of Education and Tianjin City, Tianjin, 300052, China. Electronic address: 
      jchen4@hfhs.org.
LA  - eng
GR  - R01 NS099030/NS/NINDS NIH HHS/United States
GR  - 17POST33410580/AHA_/American Heart Association-American Stroke Association/United 
      States
GR  - R01 NS097747/NS/NINDS NIH HHS/United States
GR  - R01 NS088656/NS/NINDS NIH HHS/United States
GR  - R01 NS083078/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20170901
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Neuroprotective Agents)
SB  - IM
MH  - Animals
MH  - Brain Ischemia/*complications
MH  - Humans
MH  - Mesenchymal Stem Cell Transplantation/*methods
MH  - Neuroprotective Agents/*therapeutic use
MH  - Stroke/drug therapy/etiology/surgery/*therapy
PMC - PMC5832535
MID - NIHMS904428
OTO - NOTNLM
OT  - Candesartan
OT  - Mesenchymal stromal cells
OT  - MicroRNA
OT  - Minocycline
OT  - Neurorestoration
OT  - Neurovascular remodeling
OT  - Stem cell therapy
OT  - Stroke
OT  - Synaptogenesis
OT  - Umbilical cord blood cells
OT  - White matter remodeling
EDAT- 2017/09/05 06:00
MHDA- 2018/11/09 06:00
PMCR- 2019/05/15
CRDT- 2017/09/05 06:00
PHST- 2017/06/26 00:00 [received]
PHST- 2017/08/22 00:00 [revised]
PHST- 2017/08/24 00:00 [accepted]
PHST- 2017/09/05 06:00 [pubmed]
PHST- 2018/11/09 06:00 [medline]
PHST- 2017/09/05 06:00 [entrez]
PHST- 2019/05/15 00:00 [pmc-release]
AID - S0028-3908(17)30399-4 [pii]
AID - 10.1016/j.neuropharm.2017.08.036 [doi]
PST - ppublish
SO  - Neuropharmacology. 2018 May 15;134(Pt B):310-322. doi: 
      10.1016/j.neuropharm.2017.08.036. Epub 2017 Sep 1.